Evidence map›Paper›PMID 38220187›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases.

Shuichi Okada, Junichi Okada, Kazuya Okada, Eijiro Yamada, Tsugumichi Saito, Koji Kikkawa, Tetsurou Ando, Kihachi Ohshima

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuichi OkadaDiabetes Center, Hidaka Hospital, Japan.
Junichi OkadaDepartment of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, USA.
Kazuya OkadaDepartment of Orthopedic Surgery, Tone Chuo Hospital, Japan.
Eijiro YamadaDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan.
Tsugumichi SaitoDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan.
Koji KikkawaDiabetes Center, Hidaka Hospital, Japan.
Tetsurou AndoDiabetes Center, Hidaka Hospital, Japan.
Kihachi OhshimaDiabetes Center, Hidaka Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Semaglutide is a well-designed drug with a special coating that allows for oral administration to patients with type 2 diabetes mellitus. However, patients taking oral semaglutide complain of its bitter taste. We therefore considered suggesting that patients take oral semaglutide with hot water. When the hot water temperature was increased to above 46.0°C but below 52.0°C, no bitter taste was perceived, with the daily mean interstitial glucose level remaining at the target range. Taking oral semaglutide with hot water helps reduce its bitter taste.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHot TemperatureAdministration, OralHumansHypoglycemic AgentsSemaglutideTasteWaterGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideWaterbitternesshot wateroral semaglutidetype 2 diabetes mellitus

Identifiers

PMID38220187
PMCPMC11414362

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.